Cover Image
市場調查報告書

Ezetimibe的中國市場分析 (2010∼2019年)

Investigation Report on China Ezetimibe Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 332771
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Ezetimibe的中國市場分析 (2010∼2019年) Investigation Report on China Ezetimibe Market, 2010-2019
出版日期: 2015年06月11日 內容資訊: 英文 20 Pages
簡介

隨著經濟發展和生活水準的上升,中國高血脂症的患者劇增,降膽固醇藥物的需求也急速擴大。Ezetimibe是全球第一個膽固醇吸收選擇的材料劑,2002年取得FDA (美國食品藥物管理局) 的認證。中國2007年為67萬人民幣的市場規模之後也以137%年複合成長率(CAGR) 急速成長,到2014年達到2億67萬人民幣。

本報告提供中國的Ezetimibe的市場相關分析,提供您整體市場規模和國內價格趨勢,各企業·不同投藥形態的市場佔有率,主要製造商簡介,未來性的市場趨勢預測等調查評估。

第1章 Ezetimibe的相關概念

  • 症狀
  • 全球市場的銷售情形

第2章 中國的Ezetimibe市場概況

  • 中國國內的Ezetimibe專利的申請·認證情形
  • 主要製造商
  • 市場規模

第3章 Ezetimibe銷售情形分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 中國的Ezetimibe市場:主要廠商的市場佔有率分析 (過去5年份)

  • 市場佔有率 (以銷售額為準)
  • 市場佔有率 (以銷售量為準)

第5章 中國的Ezetimibe市場:各劑型分析 (過去5年份)

  • 各劑型的市場佔有率 (以銷售額為準)
  • 各劑型的市場佔有率 (以銷售量為準)

第6章 Ezetimibe的醫院用標準價格

第7章 中國國內的Ezetimibe的主要製造商

第8章 中國的Ezetimibe市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境預測

圖表一覽

目錄
Product Code: 1506215

With the sustained economic development and the improvements in diet, Chinese people's blood fat level rises too. Many local epidemiological studies on blood fat have proved that a conservative estimate of the incidence of hyperlipemia is 7%-8% while the actual incidence might be above 10%. Over 100 million people in China have to receive cholesterol-lowering therapy, more so with the coming ageing society. As people increasingly pay attention to health, cholesterol-lowering drugs will become more and more promising. The annual market size of statin drug is estimated to surpass USD 20 billion around the world, growing at an annual rate of 20% .

Ezetimibe, the first cholesterol absorption selective inhibitor in the world, was jointly developed by Merck and Schering-Plough and approved by FDA in 2002 as the first drug for regulating blood fat with completely innovative mechanism of action after statin. Ezetimibe can selectively inhibit cholesterol transporter in the small intestine, effectively reduce cholesterol absorption, lower plasma cholesterol level and decrease the amount of cholesterol normally available to liver cells. As an ideal partner of statin, ezetimibe can provide better control rates for LDL-C with good safety and tolerance than doubled statin dose or more potent statin.

Ezetimibe in the Chinese market is monopolized by Schering-Plough. Ezetimibe develops fast after entering China with annual sales rising from less than CNY 0.05 million in 2007 to CNY 20.67 million in 2014 and CAGR during this period reaching up to 137%.

Ezetimibe enjoys a vast demand in China and its market size is expected to grow in the next few years.

Readers can get at least the following information from this report:

  • market size of ezetimibe in China
  • price of ezetimibe in Chinese market
  • market outlook of ezetimibe in China

The author suggests the following groups of people purchase this report:

  • manufacturers of lipid-lowering drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Ezetimibe

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Ezetimibe in China

  • 2.1. Patent and Approval Status of Ezetimibe in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Ezetimibe in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Ezetimibe in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Ezetimibe in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Ezetimibe in Chinese Hospitals in 2014

7. Major Manufacturers of Ezetimibe in Chinese Market, 2010-2014

8. Market Outlook of Ezetimibe in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Sales Status of Ezetimibe in China
  • Chart Sales Value of Ezetimibe in China, 2010-2014
  • Chart Sales Value of Ezetimibe in Some Regions in China, 2010-2014
  • Chart Sales Volume of Ezetimibe in China, 2010-2014
  • Chart Sales Volume of Ezetimibe in Some Regions in China, 2010-2014
  • Chart Sales Value and Market Share of Ezetimibe Made by Schering-Plough (SI) in China, 2010-2014
  • Chart Sales Value and Market Share of Ezetimibe Made by Schering-Plough (Ireland) in China, 2010-2014
  • Chart Sales Volume and Market Share of Ezetimibe Made by Schering-Plough (SI) in China, 2010-2014
  • Chart Sales Volume and Market Share of Ezetimibe Made by Schering-Plough (Ireland) in China, 2010-2014
  • Chart Sales Value and Market Share of Ezetimibe Tablets in China, 2010-2014
  • Chart Sales Volume and Market Share of Ezetimibe Tablets in China, 2010-2014
  • Chart Price of Ezetimibe Made by Schering-Plough (Singapore) in Some Chinese Cities in 2014
Back to Top